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ABSTRACT	
Adoptive	transfer	of	T-cells	genetically	modified	to	express	a	cancer-specific	T-cell	receptor	(TCR)	has	
shown	significant	therapeutic	potential	 for	both	hematological	and	solid	tumors.	However,	a	major	
issue	 of	 transducing	 T-cells	 with	 a	 transgenic	 TCR	 is	 the	 pre-existing	 expression	 of	 TCRs	 in	 the	
recipient	cells.	These	endogenous	TCRs	compete	with	the	transgenic	TCR	for	surface	expression	and	
allow	mixed	 dimer	 formation.	Mixed	 dimers,	 formed	 by	mispairing	 between	 the	 endogenous	 and	
transgenic	TCRs,	may	harbor	autoreactive	specificities.	To	circumvent	these	problems,	we	designed	a	
system	 where	 the	 endogenous	 TCR-β	 is	 knocked	 out	 from	 the	 recipient	 cells	 using	 CRISPR/Cas9	
technology,	 simultaneously	 with	 transduction	 with	 a	 cancer-reactive	 receptor	 of	 choice.	 This	 TCR	
replacement	 strategy	 resulted	 in	 markedly	 increased	 surface	 expression	 of	 transgenic	 αβ	 and	 γδ	
TCRs,	which	in	turn	translated	to	a	stronger,	and	more	polyfunctional,	response	of	engineered	T-cells	
to	 their	 target	 cancer	 cell	 lines.	 Additionally,	 the	 TCR+CRISPR	 modified	 T-cells	 were	 up	 to	 a	
thousandfold	more	sensitive	to	antigen	than	standard	TCR-transduced	T-cells	or	conventional	model	
proxy	systems	used	for	studying	TCR	activity.	Finally,	transduction	with	a	pan-cancer	reactive	γδ	TCR	
used	in	conjunction	with	CRISPR/Cas9	knockout	of	the	endogenous	αβ	TCR	resulted	in	more	efficient	
redirection	 of	 CD4+	 and	 CD8+	 T-cells	 against	 a	 panel	 of	 established	 blood	 cancers	 and	 primary,	
patient-derived	 B	 acute	 lymphoblastic	 leukemia	 blasts	 compared	 to	 standard	 TCR	 transfer.	 Our	
results	 suggest	 that	 TCR	 transfer	 combined	 with	 genome	 editing	 could	 lead	 to	 new	 improved	
generations	of	cancer	immunotherapies.	
	 	
INTRODUCTION	
Adoptive	transfer	of	genetically	engineered	T-cells	has	become	one	of	the	most	promising	avenues	of	
cancer	immunotherapy.	Numerous	trials	have	shown	objective	clinical	responses,	and	even	complete	
remissions,	 after	 adoptive	 cell	 transfer	 in	 patients	 with	 cancers	 resistant	 to	 other	 therapeutic	
interventions1–6.	The	genetic	re-targeting	of	T-cells	to	cancer	can	be	achieved	either	by	transduction	
with	 a	 chimeric	 antigen	 receptor	 (CAR)	or	 a	 T-cell	 receptor	 (TCR)	 specific	 for	 an	antigen	of	 choice.	
While	CAR-based	therapy	has	proven	extremely	successful	in	hematological	malignancies	positive	for	
CD19	(7),	CARs	can	only	target	surface-expressed	molecules.	In	contrast,	use	of	cancer-specific	TCRs	
allows	targeting	intracellular	proteome	and/or	metabolome8.	
Vertebrate	 TCRs	 exist	 as	 heterodimers	 composed	 either	 of	 αβ	 or	 γδ	 TCR	 chains.	 Conventional	 αβ	
TCRs	recognize	short	antigenic	peptides	presented	by	major	histocompatibility	complex	(MHC)	I	or	II	
molecules	(by	CD8+	and	CD4+	T-cells,	respectively).	The	targets	recognized	by	human	γδ	T-cells	tend	
to	 be	 predominantly	 proteins	 expressed	 on	 cell	 surface	 in	 context	 of	 a	 generalized	 cellular	 stress,	
including	malignant	transformation9.	A	notable	exception	to	this	rule	is	recognition	of	pyrophosphate	
metabolites	 from	 the	 mevalonate	 pathway	 (henceforth	 referred	 to	 as	 phosphoantigens)	 by	 the	
predominant	peripheral	blood	subset	of	γδ	T-cells	which	express	TCRs	comprised	of	the	Vγ9	and	Vδ2	
chains10.	Since	there	is	no	evidence	for	MHC	restriction	of	γδ	T-cells,	and	their	targets	are	expressed	
on	 a	 broad	 range	 of	 cancers,	 γδ	 TCRs	 offer	 an	 exciting	 potential	 for	 pan-population	
immunotherapy11.	
The	use	of	a	 transgenic	TCR	 in	primary,	patient-autologous	T-cells	 is	hampered	by	 the	presence	of	
pre-existing,	endogenous	TCRs	within	these	cells.	Expression	of	TCR	at	the	cell	surface	requires	the	
formation	of	a	ternary	complex	with	the	CD3	components	of	this	receptor	which	constitute	a	limiting	
factor	 for	 surface	 expression	 of	 the	 antigen-binding	 chains	 of	 the	 TCR.	 As	 a	 result,	 successful	
expression	of	transduced	TCR	at	the	cell	surface	requires	that	it	must	successfully	compete	with	the	
endogenous	TCR	chains	for	CD3	association12.	In	addition,	there	is	also	potential	for	the	formation	of	
hybrid	 TCRs	 due	 to	 mis-pairing	 of	 endogenous	 and	 transduced	 TCR	 chains	 (so-called	 mixed	 TCR	
dimers).	 Thus,	 a	 transduced	T-cell	 has	potential	 to	express	 four	distinct	TCRs,	only	one	of	which	 is	
desired.	 Mixed	 TCR	 dimers	 can	 also	 exhibit	 unpredictable,	 and	 potentially	 dangerous,	 target	
specificities,	and	have	been	shown	to	cause	fatal	autoimmunity13.	
Several	 methodologies	 have	 been	 explored	 to	 overcome	 the	 issue	 of	 TCR	 competition	 and	
mispairing.	 These	 approaches	 include	 generation	 of	 affinity-enhanced	 TCRs14,	 engineering	 of	
mutations	 to	 improve	 the	 pairing	 of	 transgenic	 TCRs15,	 or	 overexpression	 of	 CD3	 components12.	
Affinity-enhanced	 TCRs	 have	 shown	 high	 rates	 of	 objective	 clinical	 response	 since	 even	 a	 small	
number	of	 functional	TCR	molecules	 is	 sufficient	 to	convey	antigen-specific	 signaling	due	 to	 super-
physiological	 activity16.	 However,	 affinity-enhanced,	 engineered	 TCRs	 have	 bypassed	 the	 rigors	 of	
thymic	selection	and	have	potential	 to	react	 to	self	antigens.	 Indeed,	unanticipated	cross-reactivity	
by	an	affinity-enhanced	MAGE	A3-specific	TCR	with	an	epitope	from	titin	caused	fatal	autoreactivity	
in	both	patients	that	were	treated	with	T-cells	expressing	this	TCR17,18.	
Here	we	 aimed	 to	 enhance	 the	 functionality	 of	natural	 TCRs	 during	 TCR	 gene	 transfer	 of	 primary	
CD8+	and	CD4+	T-cells	by	simultaneous	knockout	of	the	endogenous	αβ	TCR	during	transfer	of	a	TCR	
of	 choice.	 This	 approach	enhanced	 the	expression	of	 the	 transduced	TCR	at	 the	T-cell	 surface	 and	
resulted	in	TCR	transductants	that	displayed	substantially	improved	antigen	sensitivity.	In	particular,	
we	 focused	 on	 leveraging	 broadly	 cancer-reactive	 γδ	 TCRs	 in	 the	 TCR	 transfer	 system	 as	 this	
approach	 can	 be	 used	 irrespective	 of	 patient	 HLA	 type.	 T-cells	 transduced	 with	 this	 system	were	
shown	 to	 have	 superior	 in	 vitro	 and	 ex	 vivo	 reactivity	 to	 primary	 hematological	 malignancies	
compared	to	T-cells	expressing	both	endogenous	and	transgenic	TCRs.	
	 	
MATERIALS	AND	METHODS	
Cell	lines	and	primary	cultures	
The	 following	 cell	 lines	 were	 purchased	 from	 ATCC	 and	 cultured	 according	 to	 manufacturer’s	
recommendations:	 Jurkat	 E6.1,	 Molt-3,	 KBM7,	 K562,	 THP-1,	 U266,	 TK6.	 The	 primary	 B-acute	
lymphoblastic	 leukemia	 (B-ALL)	cells	 (HP,	VB,	BV,	KÖ,	CM,	PH)	were	cultured	 in	defined	serum-free	
media	 as	 described	 previously19,20.	 B	 lymphoblastoid	 cell	 line	 (LCL)	 146	 was	 generated	 by	 EBV	
infection	of	peripheral	mononuclear	 cells21	 (PBMC)	obtained	 from	a	healthy	donor.	Primary	B-cells	
and	T-cells	were	 isolated	 from	PBMC	based	on	CD19	or	CD4	expression,	 respectively,	and	used	 for	
functional	 assays	 one	 day	 after	 isolation.	 HLA-A2+	 melanoma	 cell	 line	 was	 cultured	 in	 RPMI1640	
medium	supplemented	with	10%	fetal	calf	serum,	penicillin/streptomycin	and	L-glutamine	(all	 from	
Gibco,	Paisley,	UK).	T-cell	clone	γδ20	was	generated	by	single	cell	cloning	from	PBMC	as	described22.	
We	also	made	use	of	an	αβ	T-cell	clone	Mel13,	specific	for	a	Melan-A	epitope	EAAGIGILTV	presented	
in	 context	 of	 HLA-A2	 (23).	 T-cell	 clones	 and	 lines	 were	 expanded	 in	 presence	 of	 1	 µg/ml	
phytohaemagglutinin	(PHA)	and	allogeneic	irradiated	feeders	from	at	least	three	donors24.	
Generation	of	transfer	vectors	and	lentiviral	particles	
TCR	from	clone	γδ20	was	sequenced	in	house	using	SMARTer	RACE	kit	(Clontech)	and	two	step	PCR	
using	universal	forward	primers	and	reverse	primers	specific	for	constant	regions	of	TCR-γ	and	TCR-δ.	
The	γδ20	TCR	was	found	to	be	comprised	of	a	Vγ9	and	Vδ2	chain.	Mel13	is	a	sister	clone	of	Mel5	and	
the	TCR	sequence	has	been	published	before23	.	We	have	also		produced	a	TCR-peptide-HLA	A2	co-
complex	structure	of	this	TCR	with	analog25	and	natural26	antigens.		Codon	optimized,	full	length	TCR	
chains,	separated	by	a	self-cleaving	2A	sequence27,	were	synthesized	(Genewiz)	and	cloned	into	the	
3rd	 generation	 lentiviral	 transfer	 vector	 pELNS	 (kindly	 provided	 by	 James	 Riley,	 University	 of	
Pennsylvania,	PA).	The	pELNS	vector	contains	rat	CD2	(rCD2)	marker	gene	separated	from	the	TCR	by	
another	 self-cleaving	 2A	 sequence.	 For	 CRISPR/Cas9	 mediated	 knockout	 of	 both	 TCR-β	 constant	
regions	(trbc1	and	trbc2,	IMGT	website),	four	guide	RNAs	(gRNA)	targeting	the	first	exon	of	trbc	gene	
segments	were	designed	using		and	cloned	into	pLentiCRISPR	v2	plasmid28	(kindly	provided	by	Feng	
Zhang,	Addgene	plasmid	52961).	pLentiCRISPR	v2	plasmid	encodes	SpCas9	protein	and	a	puromycin	
resistance	marker	gene	(pac,	puromycin	N-acetyltransferase).	The	sequence	alignments	of	gRNAs	are	
summarised	in	Supplementary	Figure	1.		
Lentiviral	particles	were	generated	by	calcium	chloride	 transfection	of	HEK	293T	cells.	TCR	transfer	
vectors	 were	 co-transfected	 with	 packaging	 and	 envelope	 plasmids	 pMD2.G,	 pRSV-Rev	 and	
pMDLg/pRRE	while	CRISPR/Cas9	vectors	were	co-transfected	with	packaging	and	envelope	plasmids	
pMD2.G	and	psPAX2	(all	from	Addgene).	Lentiviral	particles	were	concentrated	by	ultracentrifugation	
prior	to	transduction	of	T-cells.	
T-cell	transduction	
PBMC	were	obtained	from	healthy	donors	obtained	via	the	Welsh	Blood	Service.	Primary	T-cells	were	
purified	 by	 Ficoll	 separation	 followed	 by	 magnetic	 enrichment	 for	 either	 CD8+	 or	 CD4+	 T-cells	
(Miltenyi	Biotec).	T-cells	were	subsequently	activated	overnight	by	incubation	with	CD3/CD28	beads	
(Dynabeads,	Life	Technologies)	at	3:1	bead:T-cell	 ratio.	After	activation	the	T-cells	were	transduced	
with	 lentiviral	particles	encoding	either	only	a	TCR	or	both	TCR	and	CRISPR/Cas9,	 in	presence	of	5	
µg/ml	 polybrene	 (Santa	 Cruz	 Biotechnology).	 T-cells	 that	 had	 taken	 up	 the	 virus	were	 selected	 by	
incubation	 with	 2	 µg/ml	 puromycin	 (Life	 Technologies)	 and	 magnetic	 enrichment	 with	 α-rCD2	 PE	
antibody	 (clone	 OX-34,	 Biolegend)	 followed	 by	 α-PE	 magnetic	 beads	 (Miltenyi	 Biotec).	 14	 d	 post	
transduction	 T-cells	 were	 expanded	 with	 allogeneic	 feeders22.	 For	 all	 functional	 experiments,	
transduced	T-cells	were	>95%	rCD2+.	
Flow	cytometry	
For	surface	staining,	50,000	cells	were	stained	with	Fixable	Live/Dead	Violet	Dye	(Life	Technologies)	
and	 the	 following	antibodies:	 rCD2	FITC	 (Biolegend),	pan-αβ	TCR	PE,	pan-γδ	TCR	APC,	and	CD4	PE-
Vio770	 and	 CD8	 APC-Vio770	 (where	 applicable;	 all	 from	Miltenyi	 Biotec).	 Mel13	 transduced	 cells	
were	also	stained	with	a	cognate	tetramer	(HLA-A2	refolded	in-house	with	the	EAAGIGILTV	epitope)	
according	 to	 the	 optimized	 tetramer	 staining	protocol29.	 For	 characterization	of	 the	differentiation	
phenotype	 of	 the	 transduced	 T-cells,	 the	 following	 antibodies	 were	 used:	 PD-1	 PE,	 CCR7	 PerCP-
Vio770,	 CD45RA	 PE-Vio770,	 CD45RO	 FITC,	 and	 CD27	 APC	 (all	 from	 Miltenyi	 Biotec).	 All	 cell	 lines	
tested	were	stained	with	BTN3	PE	antibody	(Biolegend),	with	or	without	zoledronate	pre-treatment.	
For	Jurkat	activation	assay,	cells	were	incubated	with	antigen	for	16	h	and	subsequently	stained	for	
CD69.	 For	 intracellular	 cytokine	 staining,	 T-cells	were	 incubated	 for	 5	 h	with	 target	 cell	 lines,	 and	
stained	for	CD107a	(BD	Biosciences),	tumor	necrosis	factor	(TNF)α	and	interferon	(IFN)γ,	according	to	
manufacturer’s	 recommendation	 (all	 from	 Miltenyi	 Biotec).	 Cells	 were	 simultaneous	 stained	 for	
combinations	of	surface	markers	rCD2,	CD3,	CD4	and	CD8	as	required.	Events	were	acquired	on	FACS	
Canto	 II	 (BD	 Biosciences)	 and	 analyzed	 using	 FlowJo	 software	 (TreeStar,	 Ashland,	 OR).	
Polyfunctionality	plots	were	generated	using	SPICE	 software30.	A	minimum	of	10,000	viable	events	
were	collected	per	sample.	
51-Chromium	release	assay	
For	the	assessment	of	cytotoxicity,	target	cells	were	pre-incubated	with	Chromium-51	(Perkin	Elmer)	
and	 then	 co-incubated	 with	 T-cells	 at	 various	 effector	 to	 target	 (E:T)	 ratios	 for	 4	 h,	 as	 described	
before29.	Cell	lysis	was	calculated	according	to	the	formula	below:	
%𝑙𝑦𝑠𝑖𝑠 = 𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙	51𝐶𝑟	𝑟𝑒𝑙𝑒𝑎𝑠𝑒 − 𝑠𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠	51𝐶𝑟	𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙	51𝐶𝑟	𝑟𝑒𝑙𝑒𝑎𝑠𝑒 − 𝑚𝑎𝑥𝑖𝑚𝑢𝑚	51𝐶𝑟	𝑟𝑒𝑙𝑒𝑎𝑠𝑒 ×100%	
Enzyme	linked	immunosorbent	assay	(ELISA)	
Briefly,	30,000	T-cells	were	co-incubated	with	90,000	target	cells	for	16	h,	and	the	supernatant	was	
harvested.	 The	 concentration	 of	 macrophage	 inflammatory	 protein	 (MIP)1-β,	 TNFα	 or	 IFNγ	 in	
supernatant	 was	 quantified	 using	 the	 respective	 detection	 kit	 (R&D	 Systems),	 according	 to	
manufacturer’s	instructions.	When	indicated,	target	cells	were	pre-incubated	with	50	µM	zoledronic	
acid	(Sigma	Aldrich)	for	16	h	and	washed	extensively	before	co-incubation	with	T-cells.	
Data	analysis	
All	data	were	analyzed	in	GraphPad	Prism	software,	unless	specified	otherwise.		
	 	
RESULTS	
Design	and	validation	of	simultaneous	TCR	knockout	and	transfer	(TCR	replacement)	system	
Lentiviral	 transduction	of	primary	T-cells	 is	greatly	enhanced	when	the	cells	are	actively	dividing	 in	
response	 to	 TCR	 and	 co-stimulatory	 signals31.	 To	 incorporate	 this	 enhancement	 and	 produce	 a	
simple,	 time-efficient	 methodology	 that	 could	 be	 applied	 with	 many	 existing	 TCR	 transduction	
systems	we	activated	T-cells	in	the	presence	of	two	separate	lentiviral	populations,	one	encoding	the	
TCR	 of	 choice	 as	 a	 transgene,	 the	 other	 CRISPR/Cas9	 targeting	 the	 endogenous	 (but	 not	 codon-
optimized)	 TCR-β	 constant	 region	 (trbc1	 and	 trbc2)	 as	 described	 in	 Materials	 and	 Methods.	 Four	
guide	RNAs	(gRNAs)	targeting	TCR-β	were	designed	and	showed	>90%	knockout	efficiency	in	Jurkat	T-
cell	leukemia	line	(Supplementary	Figure	1A).	gRNA	1	was	selected	for	use	in	primary	T-cells	due	to	
the	 high	 degree	 of	 mismatch	 between	 endogenous	 and	 the	 standard,	 codon-optimized	 TCR-β	
sequences	generally	used	during	TCR	transduction	(Supplementary	Figure	1B).	The	TCR	and	CRISPR	
lentiviruses	encoded	two	different	selection	markers	 (ectopically	expressed	rat	CD2	and	puromycin	
resistance	gene,	respectively;	Figure	1A)	allowing	selection	of	cells	that	had	integrated	the	lentiviral	
cargo.	 In	addition,	the	use	of	rat	CD2	which	was	stoichiometrically	expressed	with	the	TCR	allowed	
ready	 comparison	 between	 different	 donors	 and	 different	 transduction	 conditions	 (TCR	 only	 or	
TCR+CRISPR).	 Following	 lentiviral	 transduction,	 transduced	 cells	 were	 selected	 by	 magnetic	 or	
fluorescence-based	 sorting	 and	 culturing	 with	 puromycin,	 where	 applicable,	 followed	 by	
conventional	 T-cell	 expansion	 protocol	 (Figure	 1B).	While	 the	 selection	 of	 transduced	 cells	 by	 rat	
CD2-based	 purification	 and	 puromycin	 treatment	 resulted	 in	 nearly	 90%	 decrease	 in	 cell	 number	
(Supplementary	Figure	2A),	the	selected	cells	were	then	capable	of	expanding	to	the	same	extent	as	
untransduced	 cells	 for	 at	 least	 five	 consecutive	 expansions	 with	 allogeneic	 feeders	 and	 PHA	
(Supplementary	 Figure	 2B).	 Notably,	 transduction	 efficiency	 with	 TCR-bearing	 lentivirus	 was	
decreased	 in	 presence	 of	 CRISPR	 lentivirus,	 indicating	 that	 a	 fraction	 of	 cells	 were	 capable	 of	
accepting	only	one	of	lentiviruses	(Supplementary	Figure	2C).		
Transduction	of	primary	αβ	T-cells	with	a	γδ	TCR	on	its	own	resulted	only	in	a	minor	downregulation	
of	the	endogenous	αβ	TCR	expression.	In	contrast,	αβ	TCR	expression	was	almost	completely	ablated	
when	 cells	 were	 co-transduced	 with	 TCR	 and	 CRISPR/Cas9	 in	 all	 donors	 tested,	 showing	 high	
efficiency	 of	 the	 TCR	 replacement	 system	 (Figure	 1C).	 We	 then	 compared	 the	 expression	 of	
pyrophosphate	metabolite	specific	γδ	TCR	(γδ20),	or	a	melanoma	antigen	specific	αβ	TCR	(Mel13)	in	
primary	CD8+	αβ	T-cells	which	were	either	single	(TCR)	or	double	(TCR+CRISPR)	transduced.	While	the	
expression	of	transgenic	TCRs	in	single	transduced	T-cells	was	relatively	low	(as	detected	by	pan-γδ	
TCR	 antibody	or	 a	 cognate	Mel13	 tetramer,	HLA-A2:EAAGIGILTV),	 co-transduction	with	 the	CRISPR	
vector	resulted	in	dramatically	enhanced	expression	of	the	transduced	TCR	in	all	donors	tested	(up	to	
10-fold	increase	in	mean	fluorescence	intensity,	as	well	as	a	distinct	shift	of	histogram	peak;	Figure	
2).	High	 level	 of	 expression	of	 the	 transgenic	αβ	TCR	 in	double	 transduced	 cells	 further	 confirmed	
that	TCR-β	targeting	gRNA	was	unable	to	cleave	the	codon	optimized	receptor,	and	that	the	presence	
of	 endogenous	 TCRα	 chains	 did	 not	 have	 a	 detrimental	 effect	 on	 the	 expression	of	 the	 transgenic	
TCR.	
TCR	replacement	improves	the	functional	response	of	transgenic	T-cells	to	target	cells	
It	is	generally	acknowledged	that	the	number	of	functional	TCR	molecules	on	the	surface	of	a	T-cell	is	
one	of	 the	factors	governing	T-cell	sensitivity	to	an	antigen32.	Therefore,	we	activated	the	single	or	
double	transduced	CD8+	T-cells	with	their	target	cell	lines	(B-LCL	line	pre-incubated	with	zoledronate	
for	 γδ20	TCR,	 and	a	HLA-A2+	melanoma	cell	 line	 for	Mel13	TCR),	 and	measured	 the	percentage	of	
cells	 expressing	 a	 marker	 of	 cytotoxicity	 CD107a,	 and	 two	 cytokines	 interferon	 (IFN)γ	 and	 tumor	
necrosis	factor	(TNF)α.	The	response	of	TCR+CRISPR	transduced	T-cells	was	markedly	stronger	than	
that	 of	 cells	 transduced	 with	 only	 TCR	 (Figure	 3A	 and	 Supplementary	 Figure	 3).	 Up	 to	 90%	 of	
TCR+CRISPR	transduced	cells	expressed	at	least	one	activation	marker	in	response	to	target	cells,	and	
most	 of	 these	 cells	 expressed	 all	 three	 markers	 tested	 for,	 indicating	 a	 strong,	 polyfunctional	
response	 to	 antigen.	 Conversely,	 less	 than	 10%	 and	 40%	 of	 cells	 transduced	 only	 with	 γδ20	 and	
Mel13	TCR	respectively	were	capable	of	mounting	a	response	to	the	target	cells	-	with	only	a	small	
fraction	 of	 the	 cells	 that	 did	 respond	 exhibiting	 more	 than	 one	 function.	 In	 comparison,	 TCR	
transduced	cells	with	CRISPR	knockout	were	capable	of	mounting	a	statistically	significantly	stronger	
response	to	their	cognate	antigen	in	all	donors	tested	(Figure	3B),	and	the	response	of	TCR+CRISPR	
cells	was	comparable	to	that	of	parental	clones.	Both	TCR	only	and	TCR+CRISPR	cells	were	capable	of	
downregulating	 the	 transgenic	 TCR	 upon	 stimulation	 with	 the	 cognate	 antigen	 (Supplementary	
Figure	 4).	 Importantly,	 the	 untransduced	 and	 single/double	 transduced	 cells	 showed	 similar	
terminally	 differentiated	 effector	 memory	 phenotype33,	 plausibly	 resulting	 from	 CD3/CD28	 bead	
expansion,	but	no	signs	of	T-cell	exhaustion,	in	terms	of	PD-1	expression34		(Supplementary	Figure	5).	
TCR	replacement	improves	the	sensitivity	to	antigen	of	a	γδ	TCR	by	several	orders	of	magnitude	
T-cells	 require	 a	 given	 copy	 number	 of	 antigen	 to	 be	 present	 on	 target	 cells	 in	 order	 to	mount	 a	
successful	 response,	 thus	 defining	 the	 antigen	 sensitivity.	 While	 antigen	 sensitivity	 may	 be	
manipulated	in	case	of	αβ	T-cells	by	affinity	maturation	of	the	TCR14	so	that	it	can	robustly	respond	to	
a	 very	 limited	number	 of	 antigen	 copies35,36,	 no	 such	 technology	 has	 been	developed	 for	 γδ	 TCRs.	
Therefore,	we	decided	to	investigate	if	increasing	the	copy	number	of	γδ	TCR	on	transgenic	T-cells	by	
CRISPR/Cas9	 knockout	 of	 endogenous	 TCRs	 would	 increase	 the	 sensitivity	 to	 the	 cognate	 antigen	
HMBPP	 ((E)-4-Hydroxy-3-methyl-but-2-enyl	 pyrophosphate)	 by	 TCR-transduced	 cells.	 In	 parallel	we	
tested	 the	model	 proxy	 system	 for	 studying	 the	 role	 of	 TCR	 in	 target	 cell	 recognition;	 namely	 the	
Jurkat	T-cell	leukemia	line9.	We	measured	T-cell	response	to	the	antigen	in	terms	of	MIP-1β	secretion	
(for	 T-cells)	 or	CD69	upregulation	 (Jurkat).	 In	our	 experience,	MIP-1β	 secretion	has	been	 the	most	
sensitive	methods	for	detecting	T-cell	activation35–41.	 Indeed,	when	we	used	IFNγ	as	a	readout	of	T-
cell	activation,	we	could	not	detect	any	meaningful	response	from	γδ20	TCR-only	transduced	T-cells	
while	the	activation	of	TCR+CRISPR	cells	closely	replicated	that	of	the	parental	clone	(Supplementary	
Figure	6A).	Furthermore,	the	parental	T-cell	clone	was	more	sensitive	to	the	antigen	by	four	orders	of	
magnitude	(Figure	4)	than	the	Jurkat	cell	line	(when	using	MIP-1β	and	CD69	as	markers	of	activation,	
respectively).	More	 importantly,	 TCR-only	 transduced	 CD8+	 cells	 were	 only	 slightly	 more	 sensitive	
than	 Jurkat	 cell	 line,	 and	well	 over	 a	 thousandfold	 less	 sensitive	 than	 the	 T-cell	 clone.	 In	 contrast,	
TCR+CRISPR	transduced	cells	showed	a	similar	degree	of	antigen	sensitivity	as	the	parental	clone,	and	
were	 >50,000	 or	 >5,000	more	 sensitive	 than	 Jurkat	 or	 single	 transduced	 T-cells,	 respectively.	 The	
improvement	in	antigen	sensitivity	observed	with	Mel13	TCR+CRISPR	transduced	T-cells	compared	to	
Mel	13	TCR-only	transduced	T-cells	was	more	modest	than	for	γδ20	TCR	(~10-fold	greater	sensitivity	
in	 terms	 of	 MIP-1b	 production;	 Supplementary	 Figure	 6B	 and	 C).	 Importantly,	 the	 improvement	
observed	 with	 Mel13	 TCR+CRISPR	 T-cells	 extended	 to	 superior	 cytotoxic	 activity	 against	 HLA-A2+	
melanoma	targets	compared	to	cells	transduced	with	Mel13	TCR	only	(Supplementary	Figure	7).	
Endogenous	TCR	knockout	enhances	recognition	of	hematological	malignancies	via	a	γδ	TCR	
Vγ9Vδ2	 TCRs	 are	 known	 to	 recognize	 metabolites	 of	 the	 mevalonate	 pathway	 in	 context	 of	
butyrophilin	3A1	molecule42–44.	The	mevalonate	pathway	is	often	dysregulated	in	cancer	cells45,	and	
can	 be	 further	 modulated	 by	 aminobisphosphonates	 such	 as	 clinically	 approved	 zoledronate46.	
Vγ9Vδ2	T-cells	and	TCRs	thus	have	the	potential	to	target	multiple	different	cancer	types.	Therefore,	
we	first	tested	the	cytotoxic	activity	of	γδ20	TCR-transduced	cells	against	an	LCL	line	derived	from	the	
same	donor	 as	 the	 parental	 T-cell	 clone.	 In	 line	with	 the	 polyfunctionality	 profile	 described	 above	
(Figure	 3)	 TCR+CRISPR	 transduced	 CD8+	 cells	 were	 able	 to	 exhibit	 stronger	 cytotoxic	 activity,	
especially	at	 low	effector:target	(E:T)	ratios	(26%	vs.	4%	at	0.8	E:T,	Figure	5A)	 to	LCL	pre-incubated	
with	zoledronate.	No	cytotoxicity	was	observed	without	zoledronate	pre-treatment,	even	in	case	of	
the	 parental	 T-cell	 clone,	 thus	 indicating	 that	 the	 endogenous	 accumulation	 of	 mevalonate	
metabolites	in	that	cell	line	was	not	sufficient	to	trigger	T-cell	activation.	
Since	 Vγ9Vδ2	 T-cells	 do	 not	 require	 CD8/CD4	 co-receptors	 for	 target	 recognition,	 we	 then	
investigated	the	potential	of	TCR	replacement	system	to	redirect	both	CD8+	and	CD4+	T-cell	subsets	
to	 a	 panel	 of	 hematological	 malignancies.	We	 tested	 the	 ability	 of	 single	 (γδ20	 only)	 and	 double	
transduced	(γδ20	+	CRISPR)	T-cells	to	undergo	activation	and	cytokine	secretion	(TNFα	and	IFNγ)	 in	
response	 to	 established	 blood	 cancer	 cell	 lines	 (T	 ALL,	 acute	 myeloid	 leukemia	 (AML),	 multiple	
myeloma)	as	well	as	primary,	patient-derived	B	ALL	cells	 (Figure	5B,	Supplementary	Figure	8).	The	
primary	B	ALL	cells	used	here	have	been	previously	shown	to	closely	replicate	the	characteristics	of	
the	cancer	without	cell	culture	induced	bias19,20.	Single	transduced	T-cells	showed	only	low	reactivity,	
or	no	reactivity	at	all	(especially	in	case	of	Molt3	T	ALL	line	and	primary	B	ALL	cells)	to	hematological	
malignancies	pre-treated	with	zoledronate;	conversely,	TCR+CRISPR	transduced	cells	responded	to	all	
cell	lines	tested,	in	a	much	stronger	manner	than	the	TCR	only	transduced	cells,	even	to	cancer	cells	
expressing	 an	 almost	 undetectable	 level	 of	 BTN3	 on	 the	 surface	 (Supplementary	 Figure	 9A).	 No	
reactivity	of	γδ20	TCR	transduced	cells	(with	or	without	TCR-β	CRISPR)	was	observed	against	freshly	
isolated,	 zoledronate-treated	 healthy	 cells	 (Figure	 6),	 despite	 strong	 BTN3	 expression	 on	 the	 cell	
surface	(Supplementary	Figure	9B).		 	
DISCUSSION	
TCR	gene	transfer	has	been	proven	as	a	clinically	successful	means	of	redirecting	patient’s	 immune	
system	to	combat	different	cancer	types47.	However,	the	pre-existence	of	endogenous	αβ	TCRs	in	the	
recipient	 T-cells	 has	 limited	 the	 clinical	 use	 to	 highly	 competitive/high	 affinity	 αβ	 TCRs.	 Here	 we	
demonstrate	 that	cancer-specific	αβ	or	γδ	TCRs	 that	do	not	compete	well	with	 recipient	TCRs,	and	
therefore	 exhibit	 weak	 functional	 activity,	 can	 be	 efficiently	 used	 to	 redirect	 recipient	 T-cells	 to	
cancer	 if	combined	with	simultaneous	knockout	of	endogenous	TCR-β.	The	resultant	engineered	T-
cells	 were	 as	 sensitive	 to	 antigen	 as	 the	 starting	 T-cell	 clone	 suggesting	 that	 mispairing	 between	
endogenous	TCR-α	chains	and	transduced	TCR-β	must	be	minimal.	This	finding	is	in	accordance	with	
the	results	of	Provasi	et	al.	using	zinc	finger	nucleases	where	transgenic	TCR	activity	was	comparable	
in	T-cells	deficient	for	only	the	endogenous	TCR-β	and	both	TCR-α	and	–β48.	Furthermore,	since	TCR-
α	and	–β	chains	cannot	pair	with	TCR-γ	and	–δ	chains,	disruption	of	just	TCR-β	chain	is	sufficient	to	
achieve	the	optimal	expression	of	transgenic	γδ	TCRs.	
To	 date,	 there	 have	 been	 several	 reported	 attempts	 to	 combine	 endogenous	 TCR	 knockout,	 using	
zinc	 finger	 nucleases48,49,	 transcription	 activator-like	 effector	 nucleases50–53	 or	 CRISPR/Cas954,	 with	
redirecting	 the	 T-cells	 to	 cancer,	 in	 most	 cases	 via	 CARs.	 This	 is	 the	 first	 report	 demonstrating	
successful	 redirection	 of	 primary	 T-cells	 with	 a	 pan-cancer	 reactive	 γδ	 TCR	 in	 combination	 with	
endogenous	 TCR-β	 knockout.	We	 showed	 that	 removal	 of	 the	 endogenous	 TCR-β	 chain	 leads	 to	 a	
striking	 increase	 of	 surface	 expression	 of	 transgenic	 αβ	 and	 γδ	 TCRs	 that	 translates	 into	 a	 much	
stronger	response	of	engineered	T-cells	to	cancer	lines.	While	it	has	recently	been	shown	by	Eyquem	
et	al.	that	CAR	insertion	into	the	TCR	locus	is	beneficial	due	to	limiting	and	controlling	CAR	expression	
by	 physiological	 means,	 thus	 preventing	 premature	 exhaustion,	 the	 antigen	 binding	 kinetics	 and	
affinity	of	natural	TCRs	differ	significantly	from	that	of	CARs,	and	therefore	high	copy	number	of	TCRs	
on	 the	 cell	 surface	 appears	 more	 desirable55.	 	 Indeed,	 CRISPR+TCR	 transduced	 T-cells	 exhibited	 a	
significantly	 more	 polyfunctional	 response	 profile	 when	 presented	 with	 target	 cells	 than	 that	
observed	with	TCR-transduction	in	the	absence	of	TCR-β	knockout,	without	any	apparent	changes	in	
terms	of	T-cell	differentiation	and	exhaustion.		Importantly,	Ding	et	al.	showed	that	polyfunctional	T-
cells	are	crucial	 for	achieving	a	successful	clinical	outcome	in	patients	suffering	from	hematological	
malignancies56.	Moreover,	this	is	the	first	side-by-side	comparison	of	the	antigen	sensitivity	of	model	
Jurkat	T-cell	line,	primary	T-cells	transduced	with	a	given	TCR	and	the	parental	T-cell	clone	using	the	
most	sensitive	readouts	available.	Our	results	indicate	that	the	antigen	sensitivity	of	model	systems	
used	 in	 research	 such	 as	 Jurkat	 cells,	 or	 in	 the	 clinic	 (primary	 T-cells)	 are	 up	 to	 several	 orders	 of	
magnitude	 lower	than	that	of	the	parental	T-cell	clone,	and	that	the	sensitivity	of	the	 latter	can	be	
accurately	replicated	by	combining	TCR	transfer	with	endogenous	TCR	knockout	(TCR	replacement)	
in	 primary	 T-cells.	 Apart	 from	 having	 implications	 for	 designing	 more	 effective	 TCR-based	
immunotherapies,	 this	 result	 indicates	 that	 TCR	 replacement	 is	 preferable	 to	 TCR	 transfer	 for	
functional	 characterizations	 of	 TCRs	 of	 interest	 especially	 where	 these	 TCRs	 compete	 poorly	 with	
endogenous	 TCRs	 for	 surface	 expression	 or	 have	 a	 relatively	 low	 affinity	 for	 cognate	 antigen.	 This	
approach	 should	 also	 enable	 detailed	 analysis	 of	 TCR	 recognition	 in	 the	 absence	of	 parental	 T-cell	
clones.	Such	TCRs	may	come	from	T-cells	that	display	poor	growth	characteristics	(e.g.	as	a	result	of	
cancer-mediated	 T-cell	 exhaustion57),	 or	 directly	 from	 high	 throughput	 sequencing	 of	 TCR	
repertoires58.	 One	 can	 also	 envisage	 that	 primary	 T-cells	 transduced	 with	 a	 TCR	 of	 unknown	
specificity	 but	 not	 expressing	 the	 endogenous	 TCRs	 could	 be	 used	 for	 high-throughput,	 whole-
genome	screens28	to	identify	new	TCR	ligands,	and	therefore	new	potential	therapeutic	targets.	
γδ	 T-cells	 offer	 an	 attractive	 tool	 for	 cancer	 immunotherapy,	 due	 to	 their	 ability	 to	 recognize	
ubiquitously	 expressed	 targets	 and	no	 evidence	of	MHC	 restriction.	 This	 feature	 allows	 such	 γδ	 T-
cells	 to	 respond	 to	 cancer	 from	 any	 individual	 and	 also	 eliminates	 the	 risk	 of	 graft	 versus	 host	
disease59.	To	date,	the	majority	of	clinical	trials	utilizing	γδ	T-cells	have	focused	on	the	predominant	
subset	 in	 the	 periphery,	 namely	 Vγ9Vδ2	 T-cells,	 which	 respond	 to	 phosphoantigen	 metabolites.	
Several	multi-center	clinical	trials60–63	have	demonstrated	that	in	vivo	activation	of	Vγ9Vδ2	T-cells	and	
cancer	cell	sensitization	with	aminobisphosphonates	(zoledronate,	pamidronate)	was	well	tolerated	
and	did	not	result	in	off-target	toxicities	(despite	the	ubiquitous	expression	of	butyrophilin	molecules	
and	mevalonate	pathway	components).	Encouragingly,	aminobisphosphonate	treatment	resulted	in	
objective	 clinical	 responses	 in	 a	 fraction	 of	 patients	 with	 non-Hodgkin	 lymphoma,	 multiple	
myeloma60	 and	 AML62	 demonstrating	 the	 potential	 of	 γδ	 T-cell	 based	 immunotherapies	 for	
hematological	 malignancies.	 	 However,	 the	 therapeutic	 success	 of	 γδ	 T-cell	 immunotherapies	
remains	 underwhelming11,	 especially	 compared	 to	 CD19-CAR	 therapies64.	 One	 of	 the	 potential	
reasons	for	this	poor	success	could	be	the	use	of	variable	and	largely	undefined	(especially	in	terms	
of	TCR	usage)	cellular	product.	Furthermore,	antigen-driven	expansion	of	Vγ9Vδ2	T-cells,	as	used	so	
far,	has	been	shown	to	lead	to	exhaustion	and	loss	of	functional	activity,	in	both	animal	models	and	
in	patients65,66.	In	contrast,	TCR	replacement	by	gene	transfer,	as	utilized	here,	could	be	applied	to	a	
desirable	 T-cell	 subset	 (for	 instance,	 T	 memory	 stem	 cells)	 thereby	 potentially	 allowing	 improved	
host	engraftment	and/or	function67.	We	propose	that	using	a	defined	γδ	TCR	transferred	to	patient’s	
T-cells	in	combination	with	the	knockout	of	endogenous	αβ	TCRs	could	be	a	therapeutically	beneficial	
strategy.	 Indeed,	 TCR+CRISPR	 T-cells	 showed	 a	markedly	 stronger	 response	 (in	 terms	of	 TNFα	 and	
IFNγ	 production)	 than	 TCR-only	 transduced	 T-cells	 to	 established	 cancer	 cell	 lines,	 as	 well	 as	 all	
primary	B-ALL	blasts.		It	should	be	noted	that	TNFα	production	was	shown	to	correlate	with	cancer-
specific	activity	of	cytotoxic	T-cells,	and	elevated	 intratumoral	TNFα	concentration	could	serve	as	a	
favorable	prognostic	factor68.	Similarly,	IFNγ	is	a	potent	immunomodulatory	cytokine	that	enhances	
T-cell	mediated	 recognition	of	 cancer	 cells	 and	plays	 a	direct	 anticancer	 role69,70.	No	on-target	off-
tumor	reactivity	of	γδ20	TCR	transduced	cells	was	observed	against	primary,	aminobisphosphonate-
treated	 B-cells,	 T-cells	 or	 whole	 PBMC,	 in	 line	 with	 multiple	 clinical	 trials	 indicating	 that	
aminobisphosphonate	 treatment	 (with	 or	 without	 infusion	 of	 ex	 vivo	 expanded	 γδ	 T-cells)	 was	
generally	well	tolerated	without	severe	adverse	effects	(reviewed	in	11).	It	should	be	noted,	however,	
that	 even	with	 using	 the	 TCR	 replacement	 technology	 for	 generation	of	 Vγ9Vδ2	 TCR	 transgenic	 T-
cells,	the	patients	will	most	likely	require	bisphosphonate	treatment	for	efficient	cancer	sensitization,	
in	addition	 to	adoptive	 transfer	of	 TCR	engineered	T-cells.	 The	 increasing	 clinical	 experience	 in	 co-
administering	aminobisphosphonates	and	Vγ9Vδ2	T-cells62,71–74	will	undoubtedly	 facilitate	designing	
of	clinical	trials	testing	the	efficacy	of	Vγ9Vδ2	TCR	transgenic	T-cells.	We	therefore	believe	that	the	
TCR	 replacement	 technology	 described	 here	 would	 be	 of	 use	 in	 fundamental	 and	 translational	
research	where	 it	 could,	 for	 instance,	 be	 utilized	 to	 discover	 ligands	 of	 clinically	 relevant	 TCRs.	 In	
addition,	 this	 kind	 of	 approach	 has	 potential	 for	 developing	 a	 new	 generation	 of	 TCR-based	
immunotherapies,	 provided	 the	method	 is	 optimized	 for	 the	 clinical	 scale,	 based	on	 the	wealth	of	
experience	 in	 generating	 therapeutic	 CAR	 T-cells.	 Widespread	 clinical	 application	 of	 gene	 editing	
technology	seems	 imminent,	as	demonstrated	by	 the	 recent	 success	of	 the	off-the-shelf	allogeneic	
CAR19	 T-cells	 in	 inducing	 remission	 of	 B-ALL	 in	 infants53.	 In	 summary,	 it	 seems	 likely	 that	 TCR	
replacement	 by	 CRISPR/Cas9,	 or	 other	 means,	 will	 generate	 clinically	 useful	 T-cells	 that	 do	 not	
encompass	the	dangers	of	TCR	mispairing	and	that	can	be	orders	of	magnitude	more	sensitive	than	
the	products	currently	being	trialed.	
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FIGURE	LEGENDS	
Figure	 1.	 Construct	 design	 and	 validation	 for	 transduction	 of	 primary	 T-cells.	 (A)	 Schematic	
representation	of	transgenes	cloned	into	pELNS	vector	(top)	or	lentiCRISPRv2	vector	(bottom).	EF-1α	
-	 elongation	 factor-1	 alpha	 promoter,	 U6	 -	 RNA	 polymerase	 III	 promoter,	 pac	 -	 puromycin	 N-
acetyltransferase,	EFS	-	short	EF-1α	promoter.	(B)	Timeline	for	transduction	and	selection	of	primary	
T-cells.	 (C)	 Graphical	 representation	 of	 TCR	 expression	 on	 primary	 T-cells	 transduced	 with	 pELNS	
vector,	 with	 and	 without	 lentiCRISPRv2	 vector	 (top).	 Grey	 molecules	 represent	 endogenous	 TCR	
chains	while	blue	ones	represent	transduced	TCR	chains.	The	histograms	below	show	endogenous	αβ	
TCR	expression	 in	 three	donors	 (grey	–	untransduced,	blue	–	 transduced	only	with	a	γδ	TCR,	 red	–	
transduced	with	 a	 γδ	 TCR	 and	 CRISPR),	 as	 well	 as	 a	 representative	 unstained	 control	 (black).	 The	
color	 coding	 is	 maintained	 throughout	 the	 manuscript.	 The	 numbers	 on	 histograms	 refer	 to	
geometric	mean	fluorescence	intensities	of	αβ	TCR	expression	across	three	donors	(D1,	D2,	D3).	
	
Figure	2.	The	expression	of	transduced	TCRs	in	primary	CD8+	αβ	T-cells	derived	from	three	healthy	
donor	 PBMC	 is	 markedly	 increased	 in	 presence	 of	 CRISPR/Cas9	 specific	 for	 endogenous	 TCR-β.	
Histograms	 represent	 staining	of	 transduced	CD8+	cells	with	a	pan-γδ	TCR	antibody	 (left)	or	with	a	
HLA-A2:EAAGIGILTV	 tetramer	cognate	 for	Mel13	TCR	 (right),	while	 the	numbers	 refer	 to	geometric	
mean	intensity	of	staining.	Unstained	control	 is	shown	in	black	while	grey	represents	untransduced	
T-cells,	blue	–	transduced	only	with	a	TCR,	red	–	transduced	with	a	TCR	and	CRISPR.	
	
Figure	 3.	The	 functional	 response	 to	 target	 cell	 lines	 is	 significantly	 increased	 in	 CD8+	 T-cells	 co-
transduced	with	 TCR	 and	 CRISPR/Cas9	 specific	 for	 endogenous	 TCR-β.	 (A)	Polyfunctionality	 plots	
representing	the	response	of	transduced	and	untransduced	T-cells	 in	comparison	to	the	parental	T-
cell	 clone.	 Top	 row	 shows	 the	 response	 to	 a	 B	 LCL	 line	 pre-incubated	 with	 zoledronate	 by	 cells	
transduced	with	 the	γδ20	TCR.	Bottom	row	shows	 responses	 to	an	HLA-A2+	melanoma	cell	 line	by	
cells	 transduced	with	the	Mel13	ab	TCR.	Only	viable	CD3+	cells	were	 included	 in	 the	analysis	while	
the	gates	 for	 cells	positive	 for	 a	 given	 function	were	 set	based	on	appropriate	 fluorescence	minus	
one	 and	 biological	 controls.	 Representative	 data	 from	 two	 independent	 experiments	 and	 three	
donors	 are	 shown.	 (B)	 The	 response	of	 transduced	 T-cells	 to	 target	 cell	 lines,	 in	 terms	of	 CD107a,	
IFNγ	 and	 TNFα	 expression	 (mean	 and	 standard	 deviation	 from	 three	 donors	 are	 shown).	 The	
percentage	of	cells	that	were	positive	for	a	given	function	in	absence	of	cognate	stimulus	(i.e.	T-cells	
+	B	LCL	for	γδ20	TCR,	and	T-cells	alone	for	Mel13	TCR)	was	subtracted	from	the	percentage	of	cells	
positive	in	the	presence	of	cognate	stimulus	(i.e.	T-cells	+	B	LCL	pre-incubated	with	zoledronate	or	T-
cells	+	HLA-A2+	melanoma	cell	 line,	respectively).	 	The	statistical	significance	of	difference	between	
the	response	of	cells	transduced	only	with	TCR	or	with	TCR	+	CRISPR	was	measured	by	paired	Student	
t-test.	***p=0.0001,	**p=0.002	
	
Figure	4.	The	sensitivity	to	antigen	of	γδ20	TCR	+	CRISPR	transduced	CD8+	cells	is	higher	by	several	
orders	 of	magnitude	 than	 the	 sensitivity	 of	 CD8+	 cells	 transduced	 only	 with	 γδ20	 TCR.	 	 (A)	 The	
sensitivity	to	the	titrated	antigen	HMBPP	was	measured	either	by	CD69	mobilization	(Jurkat)	or	MIP-
1β	production	(transduced	T-cells	and	T-cell	clone)	after	overnight	incubation	with	the	antigen.	CD69	
mean	fluorescence	 intensity	or	MIP-1β	concentration	were	normalized	by	subtracting	the	values	of	
unstimulated	 cells,	 and	assuming	 the	maximum	value	 as	 100%.	 The	EC50	 values	were	 calculated	 in	
GraphPad	 Prism	 software	 by	 non-linear	 regression	 curve	 fitting.	 (B)	 EC50,	 represented	 as	 molar	
concentration	 of	 antigen	 and	 fold	 change.	 Representative	 data	 of	 two	 independent	 experiments	
carried	out	in	duplicate	are	shown.	
	
Figure	5.	T-cells	transduced	with	CRISPR	replacement	show	a	markedly	stronger	response	to	blood	
cancer	 lines	 than	with	 standard	 transduction	 techniques.	 (A)	 4	 h	 cytotoxicity	 of	 transduced	 CD8+	
cells,	 as	well	 as	 parental	 γδ20	 T-cell	 clone,	 against	 an	 untreated	 (empty	 symbols)	 or	 zoledronate-
pretreated	(filled	symbols)	γδ20	donor-autologous	B	LCL.	Representative	data	are	shown	from	three	
donors	 tested	 in	 two	experiments	 carried	out	 in	duplicate.	 (B)	 TNFα	 secretion	by	 transduced	CD8+	
(top)	or	CD4+	(bottom)	T-cells	after	overnight	co-incubation	with	a	panel	of	established	blood	cancer	
lines	of	diverse	 lymphoid	and	myeloid	origin,	or	patient-derived	B	ALL	cells.	Cancer	cells	were	pre-
incubated	 with	 zoledronate	 for	 24	 h	 before	 co-incubation	 with	 T-cells.	 TNFα	 secretion	 was	
normalized	 by	 subtracting	 TNFα	 produced	 by	 T-cells	 alone,	 and	 by	 cancer	 cells	 alone.	 No	 specific	
TNFα	 secretion	 by	 T-cells	 was	 observed	 in	 absence	 of	 zoledronate	 pre-treatment.	 Representative	
data	are	shown	from	three	donors	and	two	experiments	carried	out	in	duplicate.	
	
Figure	 6.	 Increase	 of	 γδ	 TCR	 expression	 by	 TCR-β	 knock-out	 does	 not	 enhance	 the	 targeting	 of	
normal	cells	by	engineered	T-cells.	Normal	cells	were	isolated	from	peripheral	blood	of	three	healthy	
donors	(PBMC	isolation	followed	by	magnetic	pullout	of	CD19+	B-cells	or	CD4+	T-cells)	and	incubated	
with	50	μM	zoledronate	 (where	 indicated).	On	 the	 following	day	after	 isolation,	 the	 cells	were	 co-
incubated	with	transduced	T-cells	for	16	h,	followed	by	quantification	of	secreted	TNFα	or	IFNγ.	The	
concentration	of	secreted	cytokines	was	normalized	by	subtracting	the	values	from	T-cells	incubated	
alone	and	 target	normal	cell	 incubated	alone.	Leukemia	cell	 line	THP1	and	myeloma	cell	 line	U266	
were	included	as	positive	controls.	Representative	data	from	two	TCR-transduced	donors	are	shown.		
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Supplementary Figure 1. Design and validation of gRNAs targeting trbc loci. (A) Expression of the
endogenous αβ TCR-CD3 complex on T-cell leukemia line Jurkat E6.1, untransduced (wt) and
transduced with 4 gRNAs targeting trbc gene segments (gRNA1-4). Numbers on dot plots indicate
percentage of cells expressing αβ TCR-CD3 complex. (B) Alignment of tested gRNAs to trbc1, trbc2
and codon-optimized (c.o.) trbc sequence used in transgenic αβ TCRs. Protospacer adjacent motif
(PAM) is shown in red while blue highlight indicates nucleotide match between gRNA and trbc. gRNA
sequence is shown as reverse complement in all four cases.
A B
Untransduced Jurkat cells
+rC
D2
-
 TC
R
ab
0
5
10
15
20
25
TCR only
TCR + CRISPR
tr
an
sd
uc
tio
n 
ef
fic
ie
nc
y 
[%
]
A
C
rCD2	
purification
puromycin
selection
expansion	with	
allo feeders
un
tra
ns
du
ce
d
TC
R o
nly
TC
R +
 CR
ISP
R
0
2
4
6
8
10
untransduced
TCR only
TCR + CRISPR
fo
ld
 e
xp
an
si
on
B
0 5 10 15 20 25 30
0.0625
0.125
0.25
0.5
1
2
4
8
untransduced
TCR only
TCR + CRISPR
Day in culture
ce
ll 
nu
m
be
r (
x1
06
)
Supplementary Figure 2. The kinetics and efficacy of lentiviral transduction of primary T-cells. (A)
T-cells (5×105 cells per condition) were isolated on day 0 and plated with CD3/CD28 beads. The
cells were transduced with TCR only or TCR and CRISPR lentiviruses on day 1, and cultured until day
9, followed by magnetic pullout of rCD2+ cells which were then plated with 2 μg/ml puromycin
(TCR+CRISPR only). Puromycin selection was carried out until day 14 when the transduced cells (or
a 5×105 untransduced cells) were expanded in presence of allogeneic irradiated feeders and PHA.
The cells were counted every 2-4 days by trypan blue exclusion. (B) Following the initial selection,
transduced or untransduced T-cells were expanded with allogeneic feeders and PHA every 14-28
days. The viable cells were counted after the expansion. (C) γδ20 transduced T-cells (with or
without TCR-β CRISPR) were stained for rCD2 and αβ TCR on day 9 after isolation from peripheral
blood (prior to any form of selection). Mean and standard deviation from three donors are shown.
AB
Supplementary Figure 3. Functional response of TCR-transduced CD8+ T-cells shown as individual
functions (IFNγ, CD107a, TNFα). The response of (A) γδ20 TCR-transduced CD8+ T-cells to LCL or
LCL pre-incubated with zoledronate or (B) Mel13 TCR-transduced T-cells to a HLA-A2+ melanoma.
Only viable CD3+ cells were included in the analysis while the gates for cells positive for a given
function were set based on appropriate fluorescence minus one and biological controls. Numbers
on dot plots refer to percentage of cells positive for a given function. Representative data from
three donors and two independent experiments are shown.
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Supplementary Figure 4. TCR-CD3 complex undergoes downregulation upon antigen stimulation.
γδ20 TCR transduced CD8+ T-cells and untransduced control cells were activated for 5 h with pan T-
cell stimulus PHA or γδ20 TCR specific stimulus zoledronate (zol; in presence of an LCL cell line).
Following incubation, cells were stained for CD3 and γδ TCR expression. Gating was performed to
include only the viable T-cells. At least 10,000 viable events were acquired. (A) CD3 and TCR
downregulation was calculated by dividing the geometric MFI of staining of stimulated by
unstimulated sample, after subtracting FMO values. Mean and standard deviation is shown. (B)
Representative staining for CD3 and γδ TCR. Numbers on histograms correspond to geometric MFI
of staining. FMO, fluorescence minus one.
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Supplementary Figure 5. Phenotypic profile of untransduced and transduced T-cells.
Untransduced (top row), single transduced (TCR only; middle row) or double transduced
(TCR+CRISPR; bottom row) T-cells were stained for phenotypic markers CD45RO, CD45RA, CCR7,
CD27 and PD-1. Freshly isolated PBMC were stained in parallel as a control (shown in grey).
Lymphocytes were gated based on scatter properties, followed by exclusion of doublets and dead
cells. Only CD3+CD8+ cells were taken for further analysis.
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Supplementary Figure 6. Antigen sensitivity of γδ20 and Mel13 TCR transduced CD8+ T-cells. (A) The
sensitivity to the titrated antigen HMBPP was measured by IFNγ production after overnight
incubation with the antigen and T2 cells used for antigen presentation. IFNγ concentration was
normalized by subtracting the values of unstimulated cells. (B) The sensitivity to the titrated peptide
EAAGIGILTV was measured by MIP-1β or (C) IFNγ production after overnight incubation with the
antigen and T2 cells used for antigen presentation. The EC50 values were calculated in GraphPad
Prism software by non-linear regression curve fitting.
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Supplementary Figure 7. Mel13 TCR+CRISPR CD8+ T-cells show stronger cytotoxicity
towards a melanoma cell line than Mel13 TCR-only transduced cells. 4 h cytotoxicity of
transduced CD8+ cells, as well as parental Mel13 T-cell clone, against a HLA-A2+ melanoma
cell line. Representative data are shown from two donors tested in two experiments carried
out in duplicate.
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Supplementary Figure 8. T-cells transduced with CRISPR replacement show a markedly stronger
response to blood cancer lines than with standard transduction techniques. IFNγ secretion by
transduced CD8+ (top) or CD4+ (bottom) T-cells after overnight co-incubation with a panel of
established blood cancer lines of diverse lymphoid and myeloid origin, or patient-derived B ALL cells.
Cancer cells were pre-incubated with zoledronate for 24 h before co-incubation with T-cells. IFNγ
secretion was normalized by subtracting IFNγ produced by T-cells alone, and by cancer cells alone.
No specific IFNγ secretion by T-cells was observed in absence of zoledronate pre-treatment.
Representative data are shown from three donors and two experiments carried out in duplicate.
AB
Supplementary Figure 9. Butyrophilin-3 expression on cancer cell lines and normal cells. (A)
Cancer cell lines or (B) normal cells (untreated, -ve, or treated with 50 μM zoledronate, +zol) were
stained with BTN3 antibody. The numbers on histograms refer to median fluorescence intensity of
staining. Fmo, fluorescence minus one.
